Recent studies have uncovered a frightening association between the famous diabetes and weight loss substances, Ozempic and Wegovy, with a exceptional eye disorder that may cause blindness.
A study, published in the medical journal JAMA Ophthalmology, alerted that individuals on those substances compriseing semaglutide have a much huger percentage chance of acquiring NAION, or, more accurately understandn by its acronym, non-arteritic anterior ischaemic selectic neuropathy.
This is expoundd by a deficiency of flow thcimpolite the selectic nerve, suddenly damaging one’s vision since that nerve has more than one million strands. NAION is a exceptional condition, impacting only 2 to 10 people per 100,000. It is the second directing cause of selectic nerve blindness, and there is currently no effective treatment.
The study uncovered that those using semaglutide for diabetes were four times more foreseeed to enhuge NAION than those not using the drug. Those using it for weight loss had even wonderfuler danger-more than seven times higher.
“To be perfectly evident, I would not consent my discoverings and use them to recommfinish that fortolerateings stop taking their medications,” says Dr Rizzo. “Our discovering was reassociate the first possible meaningful adverse discovering with these substances. It may equitable merit extra alert in the ponderation between doctors and fortolerateings about who may use this medicine.”
According to the study, semaglutide is joined to a seven-felderly incrrelieved danger of NAION when consentn to treat obesity and a four-felderly incrrelieved danger when used to treat type 2 diabetes.
Among the 710 fortolerateings with Type 2 diabetes, semaglutide users had an 8.9% chance of enhugeing NAION, while those on other medicines had a 1.8% chance.
The rate of NAION enhugement was 6.7% for fortolerateings deal withed semaglutide for weight loss and 0.8% for fortolerateings on other medicines.
